Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. Three weeks after PCI, new atrial fibrillation was found (no other change): a DOAC was started, ticagrelor was changed to clopidogrel and aspirin was stopped, and she has taken the DOAC and clopidogrel since. Today is her 12-month visit: she is stable and still in atrial fibrillation.
This page helps you decide: At her 12-month visit, still in atrial fibrillation: keep clopidogrel with the anticoagulant, or the anticoagulant alone from here on?
After this page you can
Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.
For Mrs. K. at 12 months, AFIRE supports stopping the antiplatelet and continuing the anticoagulant alone: noninferior for the composite of stroke, embolism, MI, unstable angina and death, about one major bleed avoided for every 88 patient-years, and more deaths in the arm that kept the antiplatelet. Hold it a little loosely: the trial stopped early, was open-label, and gave rivaroxaban in Japan at a lower dose than she would get. On the one-pager it sits on page 3, in the “On an oral anticoagulant — the trials” box (the ‘After 1 year’ row), with the Class 1 line in the recommendations box on the same page.